|
|
Other links at Articles > Pharmacists |
| 1. |
Cyclophosphamide Improves Scleroderma but Benefits Wane
|
|
|
One year of treatment with cyclophosphamide results in significant improvements in lung function, skin scores, dyspnea, and quality of life in patients with scleroderma lung disease, new findings indicate. While these effects persist for several months after treatment cessation, they are generally no longer apparent after 24 months. Reuters Health Information
|
| 3. |
Pyridoxine Metabolite Does Not Improve CABG Outcomes
|
|
|
Treatment with MC-1, a naturally occurring pyridoxine metabolite, does not reduce nonfatal MIs or cardiovascular deaths in intermediate- to high-risk patients undergoing coronary artery bypass grafting (CABG), the results of a randomized trial indicate. Reuters Health Information
|
| 4. |
Second-Generation Antipsychotics Produce Fewer Side Effects
|
|
|
Second-generation antipsychotics administered by intramuscular injection are efficacious in reducing agitation and are less likely to cause extrapyramidal adverse effects compared with first-generation antipsychotics, according to study findings published in the December issue of the Journal of Clinical Psychiatry. Reuters Health Information
|
|
|
